Consensus Novartis AG OTC Markets

Equities

NVSEF

CH0012005267

Market Closed - OTC Markets Other stock markets 14:30:07 13/05/2024 BST			5-day change	1st Jan Change
102 ^USD	+0.01%		+7.11%	+2.00%

05-13	Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales	DJ
05-10	Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation	MT

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History of analyst recommendation changes

95a51bf254ed7314ee4936f9aa4bfe6.3k1Nm2ROfq_61wApHls4gnxIkxU5_cdVYir-AfNw0fg.rAAorxF5NPyWv1BfXD9VtDIsxlgNmKwyJEenQMIisp2rHATEDj8L3smAdw~7742cb81bf06c4ca58d7b7c84397e333

Analyst Recommendations on Novartis AG

NOVARTIS AG : UBS maintains a Buy rating	05-06	ZD
NOVARTIS AG : Receives a Buy rating from Jefferies	04-26	ZD
BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	04-24	MT
NOVARTIS AG : UBS reaffirms its Buy rating	04-24	ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating	04-24	ZD
NOVARTIS AG : JP Morgan remains Neutral	04-24	ZD
NOVARTIS : 2024 has started on a strong note; guidance upgraded	04-23
NOVARTIS AG : JP Morgan gives a Neutral rating	04-23	ZD
NOVARTIS AG : Barclays keeps a Sell rating	04-23	ZD
NOVARTIS : Oddo BHF confirms its recommendation on the share	04-23	CF
NOVARTIS AG : UBS remains its Buy rating	04-23	ZD
NOVARTIS AG : Gets a Buy rating from Jefferies	04-23	ZD
Novartis Raises Guidance on Profit, Sales Growth -- Update	04-23	DJ
Novartis Raises Guidance on Profit, Sales Growth	04-23	DJ
NOVARTIS AG : UBS reiterates its Buy rating	04-18	ZD
NOVARTIS AG : Deutsche Bank maintains a Buy rating	04-18	ZD
Trending : Novartis Begins Tender Offer for MorphoSys Shares	04-11	DJ
NOVARTIS : UBS reiterates its recommendation on the stock	04-11	CF
NOVARTIS AG : UBS remains its Buy rating	04-10	ZD
NOVARTIS AG : Jefferies maintains a Buy rating	04-04	ZD
NOVARTIS AG : UBS reiterates its Buy rating	04-04	ZD
NOVARTIS AG : Gets a Neutral rating from JP Morgan	04-03	ZD
NOVARTIS AG : Barclays gives a Sell rating	03-28	ZD
NOVARTIS AG : Berenberg remains Neutral	03-25	ZD
NOVARTIS AG : Buy rating from Deutsche Bank	03-22	ZD

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

102.5 USD

Average target price

108.4 USD

Spread / Average Target

+5.76%

High Price Target

130.7 USD

Spread / Highest target

+27.45%

Low Price Target

81.17 USD

Spread / Lowest Target

-20.84%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

UBS
JEFFERIES	Peter Welford
BMO Capital
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
alphavalue	Abhishek Raval
JPMORGAN	Richard Vosser
BARCLAYS	Emily Field
BERENBERG	Kerry Holford
DZ BANK	Elmar Kraus
Kepler Capital Markets
Societe Generale
Redburn
Stifel Nicolaus
BNP Paribas
MORGAN STANLEY	Mark Purcell
Barrington Research
Credit Suisse
International Strategy & Investment Group
Morningstar
ODDO BHF
GOLDMAN SACHS	Keyur Parekh
DA Davidson
Zacks Equity Research
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH	Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK	Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Berenberg Bank
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER	Eric Le Berrigaud
LIBERUM CAPITAL	Graham Doyle
BANK OF AMERICA (BOFA)	Graham Parry

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar